SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2657Thoughts on Praulent price decrease? Perhaps with the potential updated label aFelix B-2/12/2019
2656Because it appears that I am the only one at SI who follow REGN (and is SH), i wMiljenko Zuanic-2/11/2019
2655Worth to note than SNY did not opt-out from the HD cemiplimab/SD-C + Y in P2 NSCMiljenko Zuanic-2/11/2019
2654REGN-SNY, IO breakout/split? Anyone with idea at what point SNY can develop theMiljenko Zuanic-2/10/2019
2653Not familiar with med devices clinical trials - how many years before this is ouFelix B-2/9/2019
2652RE: anti-CTLA4 (REGN4659) + anti-PD1 (Cemiplimab) in PD1/PDL1 experienced 2L /3LMiljenko Zuanic-2/9/2019
2651<Genentech has invested “well over” $1 million over the past three years in vMiljenko Zuanic-2/9/2019
2650Most likely bispecific (or costimulatory bispecific) will be ultimately (initialMiljenko Zuanic-2/8/2019
2649This IS the question. Not sure when quickest readout would be, perhaps if they Felix B-2/7/2019
2648Revised REGN-SNY collaboration agreement, how will prosper? REGN's anti-LAGMiljenko Zuanic-2/7/2019
2647Contrary, 4Q Eylea ex-US profit margin was 75%! Yes, you read it correctly! 75%!Miljenko Zuanic-2/6/2019
2646Fxxxxxx Sanofi, Dupi have $1.2B/y run rate, and they still have $88M Q-loses froMiljenko Zuanic-2/6/2019
2645Dew, Bayer was ALL-IN before Monsanto. While, Lucentis is doing better ex-US thaMiljenko Zuanic-2/6/2019
2644Bayer has no choice but to be all-in on every major product. The stock has been DewDiligence_on_SI-2/6/2019
26434Q report.....Eylea ex-US sale were $724.4 m, which is better than my estimate. Miljenko Zuanic-2/6/2019
2642REGN already list large numbers of the Ireland (Limerick) IO&PS jobs. ExpanMiljenko Zuanic-2/4/2019
2641At least 50% of the AMD subjects can be treated at >12w interval, after 6-9 mMiljenko Zuanic-1/31/2019
2640From Roche: L 4Q US sale were $432M (SF-428M), which is like "FLAT" foMiljenko Zuanic-1/31/2019
2639From Novartis, Lucentis ex-US 4Q sale were $520M (I had 510M in my book), so EyMiljenko Zuanic-1/30/2019
2638"Hundreds of jobs for Limerick as Regeneron to pump €200m into plant expansMiljenko Zuanic-1/29/2019
2637Dupi Trx; for first few weeks of 2019 Trx are bit weaker than one would assume rMiljenko Zuanic-1/27/2019
2636<Due to partnership restructuring, REGN no longer has to defer to SNY on whatMiljenko Zuanic-1/19/2019
2635Due to partnership restructuring, REGN no longer has to defer to SNY on what it DewDiligence_on_SI-1/19/2019
2634For the first time (that I follow REGN Q-results), they are reporting on WednesdMiljenko Zuanic-1/19/2019
2633timesunion.com I am bit surprise that Manufacturing building is not much largerMiljenko Zuanic-1/15/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News